Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells
- PMID: 6175965
- PMCID: PMC345938
- DOI: 10.1073/pnas.79.4.1245
Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells
Abstract
A monoclonal antibody, 9.2.27, with a high specificity for human melanoma cell surfaces has been utilized for biosynthetic studies in M21 human melanoma cells to define a unique antigenic complex consisting of a 250-kilodalton N-linked glycoprotein and a high molecular weight proteoglycan component larger than 400 kilodaltons. The 250-kilodalton glycoprotein has endoglycosidase H-sensitive precursors and shows a lower apparent molecular weight after treatment with neuraminidase. The biosynthesis of the proteoglycan component is inhibited by exposure of M21 cells to the monovalent ionophore monensin, this component can be labeled biosynthetically with 35SO4, is sensitive to beta-elimination in dilute base, and is degraded by both chondroitinase AC and ABC lyases, suggesting that it is a chondroitin sulfate proteoglycan. These data demonstrate that the antigenic determinant recognized by monoclonal antibody 9.2.27 is located on a glycoprotein-proteoglycan complex which may have unique implications for the interaction of glycoconjugates at the human melanoma tumor cell surface.
Similar articles
-
Characterization of monoclonal antibody 155.8 and partial characterization of its proteoglycan antigen on human melanoma cells.J Immunol. 1984 Apr;132(4):2096-104. J Immunol. 1984. PMID: 6199423
-
Immunochemical and biosynthetic analysis of monoclonal antibody-defined melanoma-associated antigen.Hybridoma. 1982;1(3):283-92. doi: 10.1089/hyb.1.1982.1.283. Hybridoma. 1982. PMID: 6208129
-
Serological and biochemical analyses of monoclonal antibodies to human melanoma-associated antigens.Hybridoma. 1982;1(4):423-32. doi: 10.1089/hyb.1.1982.1.423. Hybridoma. 1982. PMID: 6208137
-
Immunochemical characterization of human tumor antigens.Semin Oncol. 1986 Jun;13(2):153-64. Semin Oncol. 1986. PMID: 2424087 Review. No abstract available.
-
Production and characterization of monoclonal antibodies directed against connective tissue proteoglycans.Fed Proc. 1985 Feb;44(2):386-93. Fed Proc. 1985. PMID: 2578417 Review.
Cited by
-
Rate of internalization of an immunotoxin correlates with cytotoxic activity against human tumor cells.Proc Natl Acad Sci U S A. 1989 Jul;86(13):5146-50. doi: 10.1073/pnas.86.13.5146. Proc Natl Acad Sci U S A. 1989. PMID: 2544891 Free PMC article.
-
Activation of human peripheral blood mononuclear cells by anti-T3: killing of tumor _target cells coated with anti-_target-anti-T3 conjugates.Proc Natl Acad Sci U S A. 1986 Jun;83(12):4479-83. doi: 10.1073/pnas.83.12.4479. Proc Natl Acad Sci U S A. 1986. PMID: 3086885 Free PMC article.
-
Radioimmunoscintigraphy and immunohistochemistry with melanoma-associated monoclonal antibodies in choroidal melanoma: a comparison of the clinical and immunohistochemical results.Br J Ophthalmol. 1990 Sep;74(9):538-41. doi: 10.1136/bjo.74.9.538. Br J Ophthalmol. 1990. PMID: 2203468 Free PMC article.
-
In vivo efficacy of monoclonal antibody-drug conjugates of three different subisotypes which bind the human tumor-associated antigen defined by the KS1/4 monoclonal antibody.Cancer Immunol Immunother. 1989;28(3):171-8. doi: 10.1007/BF00204985. Cancer Immunol Immunother. 1989. PMID: 2784353 Free PMC article.
-
Acute and subacute toxicity of chemotactic conjugates between monoclonal antibody and fMet-Leu-Phe in humans: a phase I clinical trial.Cancer Immunol Immunother. 1991;32(6):406-8. doi: 10.1007/BF01741336. Cancer Immunol Immunother. 1991. PMID: 2007248 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous